Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of SYR-322 when used in combination with insulin in subjects with type 2 diabetes.

Next Previous
X
Search
Trial Profile

A multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of SYR-322 when used in combination with insulin in subjects with type 2 diabetes.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alogliptin (Primary) ; Insulin; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Takeda

    • Most Recent Events

    • 01 Dec 2009 Results were published in Diabetes, Obesity and Metabolism.
    • 09 Sep 2008 Results presented at the 44th Annual Meeting of the European Association for the Study of Diabetes.
    • 10 Jun 2008 Status change from in progress to completed

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top